Publications

Journal of Clinical Microbiology, 52(5), 1 May 2014, pp 1741-44, doi: 10.1128/JCM.03614-13
Intensive Care Medicine, 40(4), 1 April 2014, pp 564–571, doi: 10.1007/s00134-014-3225-8
Expert Opinion on Therapeutic Targets, 18(8), 1 August 2014, pp 851-61, doi: 10.1517/14728222.2014.925881

Project Partners

R-GNOSIS is coordinated by Marc Bonten (UMC Utrecht) and brings together a multidisciplinary team with complementary expertise of clinicians, microbiologists and epidemiologists, infectious disease specialists, caregivers in inpatient care and mathematical modellers. The R-GNOSIS consortium is made of 19 partners from 9 countries which include United Kingdom, Denmark, Germany, Netherlands, Belgium, France, Spain, Switzerland and Israel.

Check-Points Health, CP, NL

Check-Points Health, CP, NL


Further Information :

Organizational Activities

Check-Points Health develops, produces and sells DNA-based molecular diagnostic tests to detect antibiotic resistance in gram-negative bacteria. Multidrug resistance in gram-negative bacteria is increasing at an alarm rate and poses a huge clinical challenge. The products of Check-Points Health aim to support clinicians and hospitals in improving patient treatment and hospital hygiene. Check-Points Health is based in Wageningen, The Netherlands.

The principle of the Check-Points diagnostic system is based on specific molecular recognition of DNA target sequences and subsequent amplification with universal primers. Each single DNA target is recognized by a specific probe that contains a unique ZIP code corresponding to a unique position (address) on the microarray. These ZIP codes are used for detection on the microarray after amplification. Probes consist of two segments (probe arms), which are joined by a DNA ligase when they match perfectly with the target DNA. Only connected probe arms will result in amplification products. Probes that differ from the target DNA will not give amplification products, even in case of a single nucleotide difference. Amplification products are hybridized to the microarray and visualized by colorimetric detection. The microarrays are contained in so called Array Tubes, which are inserted in the Check-Points Array Tube Reader upon completion of the detection reaction. This generates an array image that is analyzed by dedicated software to yield a definitive and objective assay result.

Role in the Project

Key Personnel

Pieter Vos

Pieter Vos is the R&D-director of Check-Points since 2003 and is responsible for the development and production of molecular diagnostic tests for hospital-acquired infections. Previously, Pieter was the CSO of Keygene NV, a plant biotech company in Wageningen, The Netherlands. Pieter graduated cum laude in Molecular Pathology in 1983 at Wageningen University, and obtained his PhD degree at the University of Wageningen in 1987 with his work on the plant picornavirus CPMV.
- no image description is available -

Aneta Karczmarek

In her current position as a Senior Application Scientist at Check-Points (Wageningen), she ensures that the scientific and the product application knowledge gained via customer visits, scientific meetings, collaboration with external experts and reading of the scientific publication is incorporated into Check-Points tests design and shared with the Check-Points team. Previously, she worked as a postdoctoral scientist at the Department of Molecular Cytology, University of Amsterdam, Netherlands. Aneta Karczmarek obtained PhD in molecular biology (Wageningen University). During here PhD she focused on the elucidation of the relationship between nematodes and their hosts. 
- no image description is available -